BIOMARKERS FOR THE DIAGNOSIS OF INFLAMMATION-RELATED DISEASES
20190127797 ยท 2019-05-02
Inventors
Cpc classification
G01N33/5308
PHYSICS
C12Q1/6883
CHEMISTRY; METALLURGY
G01N2800/52
PHYSICS
International classification
C12Q1/6883
CHEMISTRY; METALLURGY
G01N33/53
PHYSICS
Abstract
The invention relates to new biomarkers for the diagnosis of inflammation-related diseases.
Claims
1. A method for in vitro/ex vivo diagnosing a disease in a subject, said method comprising the use of at least one nucleotide-derived metabolite selected from the group consisting of N4-acetylcytidine and adenine in a sample obtained from a subject.
2. The method according to claim 1, wherein said disease is an inflammasome-related disease.
3. The method according to claim 1, wherein said disease is a chronic inflammation, preferably a low-grade chronic inflammation, or a cardiovascular disease, preferably hypertension.
4. The method according to claim 1, wherein said disease is a cardiovascular disease induced by a chronic inflammation.
5. The method according to claim 1, wherein said subject is a human at least 60 years old.
6. The method according to claim 1, wherein said sample is blood, serum, plasma, urine, preferably serum.
7. The method according to claim 1, wherein the concentration of said at least one nucleotide-derived metabolite is determined using an assay selected from the group consisting of immunoassays, aptamer-based assays and mass spectrometry-based assays.
8. A method for in vitro/ex vivo diagnosing a disease in a subject, said disease being an inflammation-related disease, said method comprising the step of determining the concentration of at least one nucleotide-derived metabolite selected from the group consisting of N4-acetylcytidine and adenine, in a sample obtained from said subject.
9. The method according to claim 8, wherein said disease is an inflammasome-related disease.
10. The method according to claim 8, wherein said disease is a chronic inflammation, preferably a low-grade chronic inflammation, or a cardiovascular disease, preferably hypertension.
11. The method according to claim 8, wherein said disease is a cardiovascular disease induced by a chronic inflammation.
12. The method according to claim 8, wherein said subject is a human at least 60 years old.
13. A screening method for determining whether a compound would be effective in the treatment of a disease, said disease being an inflammation-related disease, comprising: a step of incubating said compound in vitro with cells that produce at least one nucleotide-derived metabolite selected from the group consisting of N4-acetylcytidine and adenine, a step of determining the extent of decrease caused by said compound on the production of said at least one nucleotide-derived metabolite.
14.-15. (canceled)
Description
FIGURES
[0179]
[0180]
[0181]
[0182]
[0183]
[0184]
[0185]
[0186]
[0187]
[0188]
[0189] (a) Analysis of immune cell type populations (ImmGen database) show that modules 62 and 78 are predominantly expressed in macrophages, monocytes and granulocytes (MP, Mn, GN respectively) (P<10.sup.10). (b) Primary neutrophils were isolated from blood of healthy donors and incubated for 24 hr with various concentrations of adenine or N4A alone or in combination, and RANK-L+ cells were determined within the CD66b+ population. (c) Primary neutrophils were treated with N4A (1 mM) and/or adenine (1 mM) and the % of degranulated population was measured for each donor. (d) Primary neutrophils were treated as before with compounds as indicated and IL-1 secretion was measured from cell culture supernatants for each donor. Data are expressed as concentration of cytokines (pg/ml), or as fold increase with respect to non-treated (NT) condition as indicated. * P<0.05, ** P<0.01
[0190]
[0191] (a) Higher levels of infiltrating T cells in kidney but not aorta are observed in treatment versus control group.
[0192] (b) Analysis of blood cells from N4A+adenine-AngII treated mice vs controls (AngII alone) shows increased levels of immune activation in granulocytes and monocytes as demonstrated by higher phosphorylation levels of signaling proteins (FDR Q<0.05). The panel shows the results of SAM analysis comparing the two groups of mice; x-axis represents the FDR or significance (cutoff 5%) as a function of score (d) parameter (y-axis), which is equivalent to the T-statistic value of a t-test when comparing two samples. pNFKB=phosphorylated form of NFKB (p65 Ser529), pCREB=phosphorylated form of
[0193] CREB (Ser133), pS6=phosphorylated form of 40S ribosomal protein S6.
EXAMPLES
Example 1
Higher Expression of Selective Inflammasome Gene Modules in Older Adults
[0194] To investigate changes in the expression of genes from immune cells in human aging, the presence of age-related genes was analyzed in the Stanford-Ellison longitudinal cohort using a modular approach for gene expression data. A gene module is defined as a set of co-expressed genes under the control of common transcription factors likely acting as regulatory programs. An important feature of this approach is that genes, regardless of their functional annotation, are organized into modules based on coordinated expression of their components; such modules may contain genes previously known to be involved in a function and those whose function is yet to be discovered. Using this approach, it was found that of a total 109 gene modules derived from data collected during the year 2008 were correlated with age (FDR Q0.05) of which only two (modules 62 and 78, composed of 82 and 17 genes, respectively) were annotated to participate in cytokine production based on gene functional annotation analysis (P<0.01). To confirm in an unbiased fashion that from the 41 age-associated gene modules only these gene modules were enriched for inflammasome-connected genes, hypergeometric tests were conducted and it was found significant enrichment for only module 62 and 78 (FDR Q<0.01) (
[0195] The module 78 contained NLRC4 and module 62 contained NLRC5 and IL1B among other genes related to inflammasome activity such as IL1RN, TLR6 and TLR8 (module 62); and IFAR1 and TLR5 (module 78). The module 62 was also annotated to participate in cell death (P<0.05), which was not surprising given that activation of inflammatory caspases may lead to rapid pyroptotic cell death besides cytokine maturation. Interestingly, these two gene modules appear to be controlled by similar transcription factors. For example, the genes BCL6, CEBPB, ETS2, MXD4 and NFIL3 were present in the regulatory programs of both gene modules (enrichment P<0.01).
[0196] To determine the stability of the age-associations for module 62 and 78, we analyzed data from samples collected over five consecutive years (2008-2012) in the Stanford-Ellison cohort. Each year consisted of both new subjects and subjects from previous years who were able to return (Table 2), and the expression of the gene modules 62 and 78 in young versus older subjects was compared using the QuSAGE gene set analysis method.
TABLE-US-00002 TABLE 2 Number of young (20-30 years) and older (60->89 years) individuals per year. 2008 2009 2010 2011 2012 Young 29 22 20 28 19 Old 60 51 55 59 52
[0197] For this analysis, samples from the individuals' first appearance in the study (N=114) were used to analyze the age associations for module expression. When considered together, these datasets show a significant age-dependent increase in baseline levels for both gene modules (
Example 2
Persistent Expression of Inflammasome Modules 62 and 78 Correlates with Hypertension, Central Arterial Stiffness and Self-Reported Familial Longevity
[0198] Because chronic inflammation has been linked to various age-associated diseases, it was investigated whether the expression of modules 62 and 78 was associated with clinical phenotypes in the aging cohorts. To do so, extreme phenotypes were defined using a classification based both on the magnitude and the chronicity in the expression levels of modules 62 and 78. Subjects were assigned into inflammasome module high (IMH) or inflammasome module low (IML) groups if they were in the upper or lower quartiles, respectively, for each gene module in 3 or more of the 5 years analyzed. Subjects who were not in either of these categories were not included in the analysis. For module 62, this analysis yielded 19 individuals with extreme phenotypes: 9 IMH and 10 IML individuals, and for module 78, 16 individuals: 9 IMH and 7 IML. It was noted a significant degree of overlap for modules 62 and 78 on each category (6 IMH and 6 IML, P-value for enrichment<0.001). Furthermore, expression levels of these two genes modules across all individuals were highly correlated (R2=0.76, P<10-5) (
[0199] Thus, to improve statistical power, IMH or IML individuals from modules 62 and 78 were combined (N=23) for further analysis. A logistic regression analysis was conducted to compare the IMH and IML phenotypes with respect to their clinical history of diabetes, hypertension and psychiatric disorders. No significant associations were found for diabetes or psychiatric disorders. However, it was found that 75% (9/12) of IMH subjects were hypertensive (essential hypertension) compared to almost none (1/11 or 9%) in the IML group. The hypertension rate for all the individuals in the older cohort (ages 60 to >89) was 52%, compared to 65% in people over 60 years old in the US20. Because the age range of our older cohorts was relatively large (60->89), age and sex were included in the logistic regression models. In addition, the analysis was adjusted for other confounding factors such as medication history (Table 3) and body mass index (BMI) (see Methods), and it was still found a significant association between hypertension and IMH/IML status (P=0.002) (
TABLE-US-00003 TABLE 3 List of medications prescribed in IML and IMH subjects. Name Mechanism of action Class Amlodipine Calcium channel blocker 1 Atacand Angiotensin II receptor antagonist 2 Atenolol Beta-blocker 3 Benicar Angiotensin II receptor antagonist 2 Candesartan Angiotensin II receptor antagonist 2 Cartia XT Calcium channel blocker 1 Carvedilol Beta-blocker 3 Chlorthalidone Thiazide diuretic 4 Diltiazem (also XR version) Calcium channel blocker 1 Diovan Angiotensin II receptor antagonist 2 Doxazosin Alpha-adrenergic blocker 5 Enalapril ACE inhibitor 6 Furosemide (AKA Lasix) Loop diuretic 7 HCTZ (hydrochlorothiazide) Thiazide diuretic 4 Lisinopril ACE inhibitor 6 Lisinopril + HCTZ ACE inhibitor + thiazide diuretic 6*4 Metoprolol Beta-blocker 3 Spironolactone Potassium-sparing diuretic 8 Triamterene Potassium-sparing diuretic 8
[0200] Based on the observation that the IMH and IML groups differed in their history of 5 diagnosed hypertension and the potential contribution of other confounders, a follow-up study was conducted to determine arterial stiffness (a stable risk factor for cardiovascular complications) using carotid-femoral pulse wave velocity (PWV) testing. The PWV, a measure of central arterial stiffness, was significantly lower in the IML group (7.92.4 m/s) compared to the IMH group (10.72.1 m/s) (P=0.02) (
[0201] Interestingly, self-reported familial longevity, as determined by belonging to a family with at least one family member over 90 years of age, was significantly higher in IML subjects (88%) compared with IMH ones (11%) (P<10-4) (
[0202] These results provide a mechanistic link explaining previous clinical observations showing that (i) the risk of developing hypertension is significantly lower in long-lived families and (ii) arterial stiffness predicts cardiovascular disease and stroke independent of age, gender and blood pressure.
Example 3
IMH Older Individuals are Chronically Inflamed with High Levels of Circulating IL1FC
[0203] The role of chronic inflammation in hypertension and vascular remodeling has gained increasing attention in the past decade and most studies have focused on important mediators of chronic inflammation such as the levels of inflammatory markers such as CRP, IL-6, TNF-, and IL-1. Thus, a comparison of circulating levels of a total of 62 cytokines and chemokines obtained from serum samples collected in the same individuals during their yearly visit in 2013 was conducted. A regression analysis on each cytokine against the IML vs IMH status was conducted and adjusted for age and sex. To obtain significance for the regression coefficients, we performed resampling analysis over 500 permutations. We found a significant increase in 17 cytokines (FDR Q<0.2) (Table 4), among which IL-1, IL-6, IL-23, IFN- and IL-17 (
TABLE-US-00004 TABLE 4 List of cytokines and chemokines associated with the IMH vs IML groups of older individuals. analyte intercept IMH_IML Sex Age TGFA 0.07153846 0.062 0.744 0.868 NGF 1 0.062 0.744 0.8266667 IL1B 0.07153846 0.1033333 0.93 0.6763636 IL31 0.775 0.1033333 0.93 1 IL23 1 0.1033333 0.5425 1 INFB 0.07294118 0.155 0.9358491 1 IL17F 1 0.1641176 0.9789474 1 IL21 0.08611111 0.1641176 0.7560976 0.868 SDF1A 0.07294118 0.1653333 0.7294118 1 IL6 1 0.1653333 0.7294118 1 MCSF 0.10333333 0.1653333 0.62 1 FGFB 0.062 0.1653333 0.7294118 1 IL12P70 0.10333333 0.186 0.7294118 1 GROA 0.062 0.186 0.62 1 IFNG 0.093 0.19375 0.7294118 0.6676923 MIG 0.18083333 0.19375 0.744 1 IL13 0.07153846 0.1972727 0.8414286 0.6716667 IL27 0.10333333 0.2066667 0.8266667 1 PIGF1 0.07153846 0.2066667 0.8414286 0.6888889 TRAIL 0.07294118 0.2066667 0.7294118 1 IL1A 0.07153846 0.2066667 0.8414286 0.6888889 TNFA 1 0.2156522 0.744 1 CD40L 1 0.2156522 0.7560976 1 IL8 0.07153846 0.2232 0.62 0.682 MIP1B 1 0.2232 0.7294118 0.7971429 MIP1A 0.07294118 0.2384615 0.8857143 1 TNFB 1 0.2755556 0.9581818 1 IL4 0.12681818 0.2993103 0.9358491 1 GCSF 1 0.2993103 0.7560976 1 IL15 0.093 0.31 0.8266667 1 IL2 1 0.32 0.9789474 1 LIF 1 0.329375 0.8857143 1 FASL 0.07153846 0.3569697 0.7294118 1 IL5 0.2325 0.4536585 1 1 EOTAXIN 0.63589744 0.4536585 0.8857143 1 SCF 0.19076923 0.4536585 1 1 IFNA 0.07153846 0.4536585 0.7560976 1 TGFB 0.22 0.4536585 0.9358491 1 MCP1 0.10333333 0.4536585 0.7294118 1 EGF 0.24424242 0.4536585 0.8266667 1 MCP3 1 0.4536585 0.7560976 1 IL10 1 0.5166667 1 1 IL17A 0.22 0.5166667 0.9789474 1 IL1RA 1 0.5166667 0.744 1 GMCSF 1 0.5166667 0.744 1 VEGFD 0.27352941 0.5166667 0.7560976 1 RESISTIN 0.16173913 0.5166667 0.744 1 VEGF 1 0.5166667 0.8266667 1 BDNF 1 0.5849057 0.6888889 1 IL18 0.22962963 0.5849057 0.8857143 1 VCAM1 0.22 0.5849057 1 1 IL22 1 0.5849057 0.775 1 LEPTIN 1 0.5849057 0.744 1 RANTES 0.90731707 0.6763636 0.5425 1 HGF 1 0.6763636 0.9789474 1 IL7 1 0.7482759 0.9358491 1 IL9 0.19076923 0.7482759 0.5166667 1 PAI1 0.63589744 0.7482759 0.7294118 1 IL12P40 0.63589744 0.8266667 1 1 ICAM1 0.53142857 0.8266667 0.7294118 1 IP10 0.22 0.9147541 0.7294118 1 PDGFBB 0.63589744 1 0.7560976 1
[0204] The largest differences were observed for IL-1, which was stably increased in the IMH group as shown by longitudinal analysis of data collected during the years 2008-2011 (
[0205] These results demonstrate that a state of immune activation with constitutive production of IL1FC and other inflammatory cytokines characterizes subjects in the IMH group compared to the IML group, which is also in agreement with two recent reports showing that gain-of-function mutations on NLRC4 cause a macrophage activation syndrome with constitutive IL-1 production.
Example 4
Nucleotide Metabolism Dysfunction and Oxidative Stress in IMH Older Adults
[0206] Maturation and release of IL1FC are controlled by the inflammasome machinery. Core components of this machinery are regulated at transcriptional (priming) and posttranscriptional (activation) levels following a plethora of inflammatory stimuli including metabolites. Given the accumulating evidence suggesting metabolic control in both steps, it was hypothesized that metabolic dysfunction may lead to the generation of potential circulating danger-associated molecular patterns (DAMPs) that trigger expression of inflammasome genes and increase production of inflammatory cytokines observed in the IMH group. To test this, a metabolomic-profiling analysis was conducted across a total of 692 metabolites that were quantified from available sera of 11 IML and 9 IMH individuals by mass spectrometry. To search for significant differences between the two groups, significance analysis of microarray (SAM) analysis was conducted. A total of 67 metabolites were significantly different between the two groups (FDR Q<0.2), all up-regulated in the IMH compared to the IML group (Table 5). Pathway enrichment analysis revealed that the metabolites found to be upregulated in IMH individuals were highly enriched for pyrimidine metabolism (P<10-4) and to a lesser extent for other pathways as well (P<0.01) (
[0207] Then, the differences in the expression levels of genes involved in these pathways were analyzed using a cutoff P-value<0.01 and a pathway impact>0.05. The analyzed metabolic pathways included pyrimidine metabolism, beta-Alanine metabolism, Pantothenate and CoA biosynthesis and purine metabolism (
[0208] Considering the importance of oxidative stress in the activation of T cells (through generation of isoketal-modified proteins in dendritic cells), the presence of markers of oxidative stress was analyzed in IMH versus IML subjects (
TABLE-US-00005 TABLE 5 List of metabolites up-regulated in IMH compared with IML older subjects. Compounds selected for experiments in primary monocytes are marked with a (*). Metabolite name Score(d) q-value(%) stachydrine 2.449 0.000 betonicine 2.429 0.000 scyllo-inositol * 2.362 0.000 5,6-dihydrothymine 2.291 0.000 N-acetylthreonine 2.272 0.000 N4-acetylcytidine * 2.238 0.000 chiro-inositol 2.208 0.000 vanillylmandelate (VMA) * 2.078 0.000 N6-methyladenosine 2.022 0.000 3-hydroxy-3-methylglutarate 2.022 0.000 S-adenosylhomocysteine (SAH) 2.004 0.000 acisoga 1.955 0.000 succinylcarnitine 1.939 0.000 adenine * 1.931 0.000 N6-carbamoylthreonyladenosine 1.884 0.000 5,6-dihydrouracil 1.874 0.000 hypotaurine 1.873 13.780 4-acetamidobutanoate 1.852 13.780 3-ureidopropionate 1.846 13.780 5-methylthioadenosine (MTA) 1.844 13.780 C-glycosyltryptophan 1.825 13.780 myo-inositol 1.811 13.780 N-acetylserine 1.778 13.780 malonate (propanedioate) 1.763 13.780 N6-acetyllysine 1.760 13.780 pyroglutamine 1.725 13.780 homovanillate (HVA) 1.720 13.780 N2,N2-dimethylguanosine 1.709 13.780 pyridoxine (Vitamin B6) 1.703 13.780 sucrose 1.677 13.780 4-hydroxyhippurate 1.676 13.780 2-aminoheptanoate 1.765 13.780 ribonate 1.670 13.780 N-acetylneuraminate 1.670 13.780 orotidine 1.667 13.780 xylitol 1.663 13.780 N3-methyluridine 1.656 13.780 corticosterone 1.652 13.780 pseudouridine 1.644 13.780 cholate 1.642 13.780 AICA ribonucleotide 1.636 13.780 dimethylglycine 1.604 13.780 3-hydroxyhippurate 1.604 13.780 xanthosine 1.595 13.780 N-methylpipecolate 1.583 13.780 citrate 1.582 13.780 hexenedioylcarnitine 1.577 13.780 N-acetylmethionine 1.575 13.780 quinolinate 1.575 13.780 behenoyl sphingomyelin 1.567 13.780 gamma-tocopherol 1.567 13.780 N-acetylalanine 1.565 13.780 O-sulfo-L-tyrosine 1.558 13.780 2-aminooctanoate 1.545 13.780 xylonate 1.541 13.780 fucitol 1.540 13.780 3-methoxytyrosine 1.500 15.966 indolebutyrate 1.495 15.966 17alpha-hydroxypregnanolone glucuronide 1.474 15.966 3beta,7alpha-dihydroxy-5-cholestenoate 1.473 15.966 2-hydroxyphenylacetate 1.466 16.880 eicosenoyl sphingomyelin 1.459 16.880 gulonic acid 1.453 16.880 N-methyl proline 1.445 16.880 3-(4-hydroxyphenyl)propionate 1.402 16.880 2-methylmalonyl carnitine 1.393 16.880 dimethylmalonic acid 1.375 16.880
[0209] In addition, we quantified circulating isoketals (8-isoprostane) and found a significant difference in IMH compared with IML subjects (
Example 5
Nucleotide Metabolites in IMH Older Adults Induce IL1FC Production in Monocytes and Activate Primary Human Platelets
[0210] The dysfunction in nucleotide metabolism and in mitochondrial bioenergetics described above may explain the generation of circulating metabolites and chronic oxidative stress, respectively. To study whether the circulating metabolites found in higher levels in the sera from IMH compared to IML subjects up-regulate NLRC4 gene expression and/or cytokine production, four candidate compounds identified from our analysis were selected. They represent distinct metabolic pathways. These included adenine (purine metabolism), DL-4-hydroxy-3-methoxymandelic acid (vanillylmandelate) (phenylalanine and tyrosine metabolism), scyllo-inositol (inositol metabolism) and N4-acetylcytidine (N4A) (pyrimidine metabolism) (Table 5). Adenosine was included as a positive control for IL1FC production. Primary monocytes from four healthy donors were isolated from fresh 20 blood and incubated with increasing concentrations of the indicated compounds for 6 hours. A significant increase in IL-1 and IL-1 was observed only for the adenosine and adenine treatments, but not with other compounds (
[0211] In parallel experiments, differentiated THP-1 cells and a human monocytic cell Line were treated to address whether the metabolites N4A and adenine, alone or in combination, could induce inflammasome activation and cytokine secretion in vitro. It was found that neither incubation with adenine nor with N4A alone had an effect in the production of IL-1, IL-18 (another IL1FC) or TNF- (
[0212] Moreover, co-treating cells with adenine and N4A induced a significant increase in IL-1 and IL-18 levels (
[0213] This shows that the presence of both N4-acetylcytidine and adenine may provide both signals necessary for inflammasome activation and secretion of IL1FC from human monocytes.
[0214] Platelet activation is a critical step in various inflammatory conditions of both infectious and non-infectious origins and accumulating evidence indicates that hypertensive patients exhibit high levels of activated platelets compared with healthy controls. Putative mechanisms that contribute to platelet activation in hypertension include endothelial dysfunction, neurohumoral (sympathetic and renin-angiotensin systems) overactivity, decreased platelet nitric oxide (NO) biosynthesis, and platelet degranulation secondary to increased shear. An important feature during platelet activation was described in a recent study of dengue infection, where platelets from infected patients or those infected with dengue in vitro activated the NLRP3 inflammasome and induced a caspase-1 dependent IL-1 secretion35. Thus, it was sought to determine whether N4A and adenine were able to activate human platelets in vitro. To do so, platelets were isolated from the blood of two healthy donors and incubated for 6 hrs at 37 C. with various concentrations of adenine or N4A. Thrombin, and ADP were used as controls and platelet activation was monitored by measuring membrane expression of CD61 and CD62P+ cells by flow cytometry. It was observed that adenine robustly induced a dose-dependent increase in the percentage of activated platelets (in contrast to N4A), comparable to the positive control with ADP (
[0215] Analysis of the various immune cell types involved in the expression of the age associated gene modules studied here, showed that modules 62 and 78 were preferentially expressed in monocytes, macrophages and neutrophils (P<10.sup.10) (
Example 6
Effect of N4A and Adenine on Blood Pressure in an Experimental Mouse Model
[0216] To study whether the selected compounds had a direct effect on blood pressure in vivo, mice were injected with N4A plus adenine at the indicated concentrations daily and changes in blood pressure were monitored using a tail cuff method during a total of 34 days. Treatment with N4A and adenine had a mild effect with borderline significant increases in blood pressure (pre-hypertension) as early as 8 days after the first injection (P=0.04 for group comparison) (
[0217] Overall these data show that the presence of both N4A and adenine is necessary for production of IL1FC from human monocytes, activation of platelets and blood pressure elevation in mice.
[0218] This experiment was repeated using 10 mice per group and collected from the same mice and at the end of study peripheral blood samples as well as tissue samples from kidney and aorta, from a total of 6/10 mice per group.
[0219] At the tissue level, a substantial T cell infiltration in the kidneys (cortex) was observed but not the aorta in N4A+ adenine-treated mice compared to controls (P=0.001) (
[0220] Mass cytometry (CyTOF) was used to investigate the levels of immune activation markers in 18 multiple blood cell subsets including granulocytes, monocytes, NK cells CD4 and CD8 T cells, T regulatory CD4 T cells and B cells. In all these cell subsets, the NFkB inhibitor IkB and the activation marker CD62L were compared, as well as the levels of a series of phosphorylated intracellular signalling proteins including CREB, STAT1, STAT3, STAT5, p38, S6, NFkB, ERK and MAPKAPK2 between compound-treated and control mice. A general state of immune activation was observed as evidenced by higher levels of pS6 and pCREB in monocytes and in granulocytes and increased pNFkB in monocytes (
[0221] Remarkably, the levels of total IkB were also higher in monocytes and granulocytes. The fact that the levels of total IkB and those of pNFkB were elevated in compound-treated mice versus controls indicates that chronic stimulation of immune cells with these nucleotide metabolites may induce an activation state similar to that observed in previous reports showing that oscillating NFkB phosphorylation/translocation is necessary for gene transcription when the stimulation is heightened for long periods of time. Under acute conditions a reduction of total IkB tracks with increased pNFkB levels. However, under chronic conditions, the initial reduction in IkB signaling following stimulation returns to baseline at a time when pNFkB is still elevated.
[0222] Overall these data show that the chronic presence of these nucleotide metabolites generates a state of systemic inflammation that leads to T cell infiltration in kidneys and the elevation of blood pressure.
Example 7
Caffeine Negatively Correlates with Expression of Inflammasome Gene Modules 62 and 78
[0223] Lowering chronic inflammation in older people may prevent the appearance and delay the clinical symptoms of a number of age-associated diseases. Since adenine and adenosine derivatives were found in high amounts in the IMH group and play a key role in the regulation of IL1FC production, it was asked whether caffeine, a methylxanthine and adenosine antagonist was associated with inflammasome module gene expression. To do so, a questionnaire consisting of a 15-item survey of dietary and pharmaceutical sources of caffeine was administered. For each of the 15 categories in the survey, an approximate caffeine value was derived from 120 of the most commonly consumed caffeinated products in the United States in 2007. A multiple regression analysis was performed using data from all individuals in the year 2008 (N=89) on the expression of modules 62 and 78 and caffeine intake (in mg/week). For these analyses, it was also adjusted for BMI, a known confounding factor associated with caffeine intake. A significant age-, sex- and BMI-adjusted association was found between caffeine intake and expression of modules 62 (P<0.01) and 78 (P=0.024) (
[0224] We then compared the levels of caffeine and caffeine-derived metabolites in the sera from IMH and IML subjects. To do so, we used the metabolomics data previously generated and directly compared serum levels of caffeine and its metabolites paraxanthine, 1,3,7-trimethyluric acid, theophylline, theobromine and 1-methylxanthine, without adjusting for multiple comparisons. It was found that when considered jointly, the differences for all six compounds combined were statistically significant between the IML and IMH groups (P<0.01) (
[0225] These results indicate that caffeine intake negatively correlates with expression levels of gene modules 62 and 78 and the circulating levels of this methylxanthine and, when considered jointly, its metabolites are increased in IML subjects compared with IMH ones. Thus, it is possible that moderate coffee consumption may be beneficial to decrease inflammatory processes, by its known effect on the inhibition of adenosine and adenine, which may account in part for the reported correlation with decreased mortality.
Example 8
Clinical Study in a 100-Hypertensive Patient Cohort
[0226] This clinical study is designed in order to validate the implication of the adenine and adenosine derivatives in hypertension.
[0227] An ultrahigh performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) protocol for the quantification of N4-acetylcytidine and adenine is undergoing its method validation (specificity, linearity, calibration interval, yield, precision, accuracy). 100 hypertensive patient blood samples are subjected to N4-acetylcytidine and adenine quantification by means of this protocol.
[0228] The results are correlated to the ones of healthy subject blood samples to validate the statistical significance of N4-acetylcytidine and adenine as biomarkers for in vitro hypertension detection.
[0229] Materials and Methods
[0230] Study Design, Subjects and Sample Collection
[0231] One hundred and fourteen donors (ages 20 to >89) were enrolled in an influenza vaccine study at the Stanford-LPCH Vaccine Program during the years 2008 to 20131-3 (ClinicalTrials.gov registration NCT#01827462). Since baseline samples were obtained from all the individuals prior to vaccination with the influenza vaccine, no randomization or blinding was done for this study. The protocol for this study was approved by the Institutional Review Board of the Research Compliance Office at Stanford University.
[0232] Informed consent was obtained from all subjects. All individuals were ambulatory and generally healthy as determined by clinical assessment. At the time of initial enrollment volunteers had no acute systemic or serious concurrent illness, no history of immunodeficiency, nor any known or suspected impairment of immunologic function, including clinically observed liver disease, diabetes mellitus treated with insulin, moderate to severe renal disease, blood pressure>150/95 at screening, chronic hepatitis B or C, recent or current use of immunosuppressive medication. In addition, on each annual vaccination day, none of the volunteers had been recipients or donors of blood or blood products within the past 6 months and 6 weeks respectively, and none showed any signs of febrile illness on day of baseline blood draw. Peripheral blood samples were obtained from venipuncture and whole blood was used for gene expression analysis (below). Serum was separated by centrifugation of clotted blood, and stored at 80 C. before cytokine and chemokine determination.
[0233] Gene Expression Analysis
[0234] Two different microarray platforms were used to generate expression data from whole blood samples obtained from a total of 114 individuals recruited as part of the Stanford-Ellison cohort1-3; the Human HT12v3 Expression Bead Chip (Illumina, San Diego, Calif.) for years 2008 and 2009, and the GeneChip PrimeView Human Gene Expression Array (Affymetrix, Santa Clara, Calif.), for years 2010, 2011 and 2012. For the Illumina platform, biotinylated, amplified antisense complementary RNA (cRNA) targets were prepared from 200 to 250 ng of the total RNA using the Illumina RNA amplification kit (Applied Biosystems/Ambion). Seven hundred and fifty nanograms of labeled cRNA was hybridized overnight to Illumina Human HT-12v3 BeadChip arrays (Illumina), which contained >48,000 probes. The arrays were then washed, blocked, stained and scanned on an Illumina BeadStation 500 following the manufacturer's protocols.
[0235] BeadStudio/GenomeStudio software (Illumina) was used to generate signal intensity values from the scans. For normalization, the software was used to subtract background and scale average signal intensity for each sample to the global average signal intensity for all samples. A gene expression analysis software program, GeneSpring GX version 7.3.1 (Agilent Technologies), was used to perform further normalization. For the Affymetrix platform standard Affymetrix 3IVT Express protocol was used to generate biotinylated cRNA from 50-500 ngs of total RNA. DNA polymerase was used for the production of double stranded cDNA. T7 RNA polymerase, in the presence of biotinylated nucleotides, was used for in vitro transcription (IVT) of biotinylated cRNA.
[0236] The fragmented and labeled targets were hybridized to the PrimeView Human Gene Expression Array cartridge, which measure gene expression of more than 36,000 transcripts and variants per sample by using multiple (11 probes per set for well annotated sequences, 9 probes per set for the remainder) independent measurements for each transcript. The standard Affymetrix hybridization protocol includes 16 hr (overnight) hybridization at 45 degree at 60 rpm in an Affymetrix GeneChip Hybridization Oven 645. The arrays were then washed and stained in an Affymetrix GeneChip Fluidics Station 450. The arrays were scanned using the Affymetrix GeneChip Scanner 3000 7G and the Affymetrix GeneChip Command Console Software (AGCC) was used for the gene expression data processing and extraction. The raw data for years 2008 through 2012 has been deposited on the Immunology Database and Analysis Portal (ImmPort) under accession numbers SDY314, SDY312, SDY311, SDY112 and SDY315, respectively. To identify gene modules associated with IL1FC production and inflammasome activity, a list of a total of 89 genes including the Pattern-Recognition Receptor family and their positive and negative regulators encompassing TLRs, NLRs, RIG-I-Like Receptors (RLRs), C-type lectin-like Receptors (CLRs) and their adaptors; inflammatory caspases and their direct regulators; and transcription factors involved in NF-kB and Type-I Interferon (IFN) signaling which are known to regulate inflammasome gene expression and activation was gathered from manually curated data. The presence of these genes was searched across a total of 109 previously defined gene modules. A gene module corresponds to a set of co-expressed genes sharing regulatory programs. Briefly, data were filtered by variance and a total of 6234 highly variant genes were normalized by centering and scaling the expression, so that each gene's expression across all subjects had euclidean norm equal to 1 for purposes of clustering. Data was log transformed to approximate to normal distribution. A hierarchical agglomerative clustering was used with average linkage, euclidean distance and a height cutoff value of 1.5 to derive 109 modules. For each gene module, it was assigned a set of regulatory genes (regulatory program), based on regression analysis of genes in the modules onto expression of known transcription factors using a Akaike Information Criterion (AIC)6. To do so, a linear regression was performed with elastic net penalty of each module's expression onto a set of 188 transcription factors using LARS-EN algorithm. To select the best model among the outputs of LARS-EN, quality of the resulting models by AIC was assessed with sample specific terms weighted by within-module variance. The fit with the best AIC score was selected for each module.
[0237] To determine the stability of the age-associations for module 62 and 78, the QuSAGE gene set analysis method was used. It creates a probability distribution representing the mean and standard deviation of a set of genes and enables comparisons of gene sets across different groups. For this analysis, samples from the individuals' first appearance in the study were used to analyze the age associations for module expression.
[0238] The presence of extreme phenotypes was examined by using classification based on the magnitude and stability (chronicity) of the expression levels. For each year, the expression of modules 62 and 78 were used to bin subjects into quartiles. Subjects were assigned into inflammasome module high (IMH) or inflammasome module low (IML) groups if they were in the upper (top 25% of subjects) or lower quartile (bottom 25%) in at least in 3/5 years, respectively. Subjects who were not in the upper or lower quartiles in at least 3/5 years were not included in this analysis.
[0239] Determination of Cytokines, Chemokines and Growth Factors
[0240] I. Polystyrene bead kits: Human 50-plex (for year 2008) or 51-plex (for years 2009-2011) kits were purchased from Affymetrix and used according to the manufacturer's recommendations with modifications as described below. Briefly, samples were mixed with antibody-linked polystyrene beads on 96-well filter-bottom plates and incubated at room temperature for 2 h followed by overnight incubation at 4 C. Room temperature incubation steps were performed on an orbital shaker at 500-600 rpm. Plates were vacuum filtered and washed twice with wash buffer, then incubated with biotinylated detection antibody for 2 h at room temperature. Samples were then filtered and washed twice as above and re-suspended in streptavidin-PE. After incubation for 40 minutes at room temperature, two additional vacuum washes were performed, and the samples resuspended in Reading Buffer. Each sample was measured in duplicate. Plates were read using a Luminex 200 instrument with a lower bound of 100 beads per sample per cytokine. Custom assay Control beads by Radix Biosolutions are added to all wells.
[0241] II. Magnetic bead Kits. Serum specimens were collected from blood samples and frozen in aliquots at 80 C. Human 63-plex (for year 2013) kits were purchased from eBiosciences/Affymetrix, of which 62 analytes passed QC; and used according to the manufacturer's recommendations with modifications as described below. Briefly: beads were added to a 96 well plate and washed in a Biotek ELx405 washer. Samples were added to the plate containing the mixed antibody-linked beads and incubated at room temperature for 1 hour followed by overnight incubation at 4 C. with shaking. Cold and Room temperature incubation steps were performed on an orbital shaker at 500-600 rpm. Following the overnight incubation plates were washed in a Biotek ELx405 washer and then biotinylated detection antibody added for 75 minutes at room temperature with shaking. Plate was washed as above and streptavidin-PE was added. After incubation for 30 minutes at room temperature wash was performed as above and reading buffer was added to the wells. Each sample was measured in duplicate.
[0242] Plates were read using a Luminex 200 instrument with a lower bound of 50 beads per sample per cytokine. Custom assay Control beads by Radix Biosolutions are added to all wells. Mean fluorescence intensities (MFIs) were recorded and used for further analysis. To identify differences between IH and IL individuals in an unbiased fashion, data were analyzed from year 2013 since this was the year with the largest number of measured analytes (N=62). A multiple regression analysis was conducted on each analyte MFI against IH/IL status, age and sex and obtained significance for each regression coefficient via permutation tests over 500 resamplings. To study whether the differences in IL-1 and IL-1 observed in IH subjects compared to IL ones were longitudinally stable, the levels of 25 IL-1 and IL-1 from data generated in the years 2008 through 2011 were compared between IH and IL subjects, using regression model with IL-1 or IL-1 MFI against IH/IL status, age and sex without multiple hypothesis correction.
[0243] Combined data showed homoscedasticity based on Bartlett's test. Cytokine data from 2012 was not included in this analysis because data from only 14 extreme phenotype individuals was available. P-values for years 2008 through 2011 were combined using a modified generalized Fisher method for combining P-values from dependent tests.
[0244] Cardiovascular Phenotyping
[0245] A subgroup of patients (N=17) from the Stanford-Ellison cohort underwent comprehensive cardiovascular assessment at Stanford Cardiovascular Institute Biomarker and Phenotypic Core Laboratory. Vascular studies included the measurement of both carotid intima-media thickness (cIMT) and central aortic pulse wave velocity (PWV). A 9.0 MHz Philips linear array probe was used for carotid and femoral measurements. The cIMT was the average of the anterior, lateral, and posterior measurements and averaged for both the right and left carotid artery. Aortic PWV was calculated as the path length travelled and divided by transit time of the aortic pulse wave and reflects arterial stiffness. Path length (D) was measured as the distance from the sternal notch to the femoral artery minus the echocardiographic distance from the sternal notch to proximal descending aorta.
[0246] Metabolomics Data Generation and Analysis
[0247] Metabolomic data were conducted at Metabolon as described previously using nontargeted metabolomic profiling. Briefly, serum samples from IMH (N=11) and IML (N=9) were subjected to methanol extraction then split into aliquots for analysis by ultrahigh performance liquid chromatography/mass spectrometry (UHPLC/MS) in the positive, negative or polar ion mode and by gas chromatography/mass spectrometry (GC/MS). Metabolites were identified by automated comparison of ion features to a reference library of chemical standards followed by visual inspection for quality control.
[0248] For statistical analyses and data display, any missing values were assumed to be below the limits of detection; these values were imputed with the compound minimum (minimum value imputation). To determine statistical significance, Significance Analysis of Microarrays (SAM)12 was conducted on the residuals from a multiple regression model which included age and sex as covariates. A Q-value<0.05 was used as an indication of high confidence in a result. A total of 67 differentially regulated metabolites were observed in IML versus IMH individuals. Pathway analysis was conducted using MetPA13 which combines several advanced pathway enrichment analysis along with the analysis of pathway topological characteristics across over 874 metabolic pathways. For over representation and pathway topology analyses, hypergeometric test and relative-betweeness centrality were used, respectively.
[0249] Differential Expression of Purine and Pyrimidine Metabolism Genes
[0250] A total of 104 pyrimidine metabolism genes (PYR) and 54 genes participating in purine metabolism (PUR) were obtained from KEGG14. Regression analysis was conducted on each gene's expression using microarray data from year 2008 against IML/IMH status, while adjusting for age and sex. Significance for each regression coefficient was obtained via permutation tests. Genes differentially expressed were subjected to enrichment analysis by hypergeometric test. A P-value<0.05 was used as an indication of high confidence in a result.
[0251] Compound Treatment, Cytokine Secretion and qPCR Assays
[0252] Adenosine, adenine, DL-4-hydroxy-3-methoxymandelic acid, scyllo-inositol were all purchased form Sigma (Sigma-Aldrich, St. Louis, Mo.) and N4-acetylcytidine was purchased from Santa Cruz Biotechnology (Dallas, Tex.). Compounds were tested at the indicated concentrations on isolated monocytes from a healthy donor. Whole blood was obtained from venipuncture (30 ml) and monocytes were enriched using the RosetteSep Human Monocytes Enrichment Cocktail (cat # 15068, Stemcell Technologies, Vancouver, BC, Canada) according to the manufacturer's recommendations. Cells were plated on 96-well plates at a density of 310-5 cells in 200 uL LGM-3 serum-free media (Lonza) and incubated for 6 hours at 37 C. Supernatants were collected, frozen immediately and stored at 80 C. Samples were then transferred to the Human Immune Monitoring Core at Stanford for quantification of cytokines, chemokines and growth factors using the 63-plex Luminex system, as described above.
[0253] To assess significance for the dose-response experiments we used Short Time-series Expression Miner (STEM) which uses clustering methods for time-series or dose response experiments and allows for the identification of significant dose-dependent profiles. RNA was extracted from cell pellets using the RNeasy Micro Kit (Qiagen) following the manufacturer's recommendations. cDNA was prepared using the SuperScript VILO cDNA Synthesis Kit (Life Technologies). NLRC4 and NLRP3 expression was measured by quantitative PCR using pre-design TaqMan Gene Expression Assays (Life Technologies) and plates were run on a StepOne Real Time PCR System (Applied Biosciences). Expression of GAPDH was used to standardize the samples, and the results are expressed as a ratio relative to control.
[0254] Hypertension Studies in Mice
[0255] Adult male mice (12-18 week old) were divided into two groups: PBS or compound treated-mice (N4-Acetylcytidine+Adenine dissolved in PBS). Compound-treated mice were injected with N4-Acetylcytidine and Adenine (stock solution 20 mM each, 100 ul/25 g body weight, retro-orbital injection, once daily) or PBS. After 3 weeks of treatment, while they continued receiving daily injections of PBS or N4A+Adenine, mice from both groups were administered an infusion of human angiotensin II (AngII, #A9525, Sigma-Aldrich, St. Louis, Mo.) for another 2 weeks. Angll (140 ng/kg per min) was dissolved in 100 ul 20 mM (N4A+Adenine) or in 100 ul PBS and loaded into a small osmotic pump (Durect Corporation, Cupertino, Calif., USA). The osmotic pump was then implanted subcutaneously on the dorsal side around the neck of mice under anesthesia (2% oxygen, 2.5% isoflurane). Systolic blood pressure was measured every other day in conscious mice using tail-cuff plethysmography (Vistech System BP-2000, Apex, N.C., USA). Experiments with human THP-1 cells and primary blood platelets THP-1 monocytic cell lines were cultured in 6-well plates in RPMI media (supplemented with 10% Fetal Bovine Serum) and differentiated overnight with TPA (10 ng/ml). The day after, adherent cells were washed with fresh media and treated with agonists LPS (1 ng/ml, 4 hrs) and ATP (5 mM, 30 min) or compounds Adenine/N4-Acetylcytidine at various concentrations.
[0256] Human primary platelets were prepared from whole blood using a venepuncture in EDTA tube after a 20 min centrifugation at 1000 rpm without acceleration and break. Then the supernatant was harvested and 1 M PGE1 was added. After gentle centrifugation (10 min at 2000 rpm without break), supernatant was removed and Tyrode buffer was added. Platelets were then stimulated with thrombin (at 0.5 U/ml), ADP, or with the indicated concentrations of N4A or adenine, and activation was monitored by flow cytometry using 25 immunostaining of membrane markers with anti-CD61 (marker of platelet population), and anti-CD62-P (marker of activation involved in aggregation).